2023年更新的MASCC/ESMO共识建议:预防高风险抗瘤剂后的恶心和吐
Jørn Herrstedt1,2, L Celio3, P J Hesketh4
1Department of Clinical Oncology, Zealand University Hospital, Sygehusvej 10, DK-4000, Roskilde, Denmark. jherr@regionsjaelland.dk.
更新的指导方针建议使用4天的类固醇治疗方案进行非环素/环胺高风险化疗 (HEC) 和奥兰扎作为所有HEC四种药物抗疗方案的关键成分.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 基于证据的医学基于证据的医学.
背景情况:
- 系统审查更新 2016-2017 MASCC/ESMO对高风险化疗 (HEC) 的建议.
- HEC包括特定的药物和组合,如乳腺癌的循环胺/人类循环素 (AC).
结论:
- 只有在AC HEC后的第1天才建议服用类固醇 (德甲);对于非AC HEC,建议使用4天的治疗方案.
- 现在,olanzapine是AC和非AC HEC的四种药物抗疗法的推成分.
- 在5-HT3或NK1受体对抗剂之间没有发现显著差异;没有新的抗药符合纳入标准.
更多相关视频
05:33Author Spotlight: Alleviating Nausea and Vomiting in Pregnancy with Safe and Effective Auricular Acupuncture
Published on: August 4, 2023
07:29Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
相关概念视频
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
Two synthetic agonists of THC,...
Nursing Ethical Principles II
Consider the following scenario, which illustrates how these principles are applied in the care of Mr. John, a fifty-year-old teacher diagnosed with metastatic liver cancer.
Initially, Mr. John's...
Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
